35,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 35,000 shares of the company’s stock, valued at approximately $2,972,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its stake in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after buying an additional 369 shares during the period. First Horizon Corp acquired a new position in Abivax in the 3rd quarter valued at about $36,000. Hantz Financial Services Inc. purchased a new stake in Abivax during the 3rd quarter valued at approximately $52,000. Gordian Capital Singapore Pte Ltd purchased a new stake in Abivax during the 3rd quarter valued at approximately $76,000. Finally, Covestor Ltd acquired a new stake in Abivax during the 3rd quarter worth approximately $96,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Citizens Jmp boosted their target price on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a report on Tuesday, December 16th. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Truist Financial set a $140.00 price objective on shares of Abivax in a research report on Monday, November 24th. Piper Sandler restated an “overweight” rating and set a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Finally, BTIG Research restated a “buy” rating and issued a $150.00 target price on shares of Abivax in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $136.69.

Abivax Stock Performance

Shares of ABVX stock opened at $123.99 on Thursday. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock has a 50 day simple moving average of $119.08 and a 200-day simple moving average of $109.81. The company has a market cap of $9.80 billion, a price-to-earnings ratio of -29.66 and a beta of 1.00. Abivax SA Sponsored ADR has a 12-month low of $4.77 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million during the quarter. On average, equities analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.